KPI Therapeutics careers

KPI Therapeutics is developing game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as atopic dermatitis, myositis, and lupus, KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments.